New inhibitor against prostate cancer.
Posted by giorgiobertin on January 10, 2024
A team of researchers from Faculty of Medicine of the University of Freiburg has developed an active ingredient that could represent a new therapeutic option for prostate cancer in the future.
This substance, known as KMI169targets an enzyme KMT9, known as methyltransferase which plays an important role in the development of prostate cancer. The KMI169 inhibitor has shown enormous potential, among other things, in cancer cells resistant to conventional treatments.
“The inhibitor fits perfectly like a key in a lock and blocks the functioning of KMT9 and therefore also the growth of both prostate and bladder cancer cells“, says the prof. Jung. The development of KMI169 was guided by analysis of the crystal structure of KMT9 and numerous other studies. “We have modified the compound many times to increase its potency, selectivity and medicinal properties”.
The potential use of KMI169 against treatment-resistant forms of cancer, including bladder cancer, makes it particularly valuable. The development of KMI169 indeed represents a notable step forward in the field of cancer research.
The publication in the magazine “Nature Communications“.
Read the full text of the article:
Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.
Wang, S., Klein, S.O., Urban, S. […] Manfred Jung, Eric Metzger & Roland Schüle
Nat Commun 15, 43 (2024).
Source: Medical Faculty of the University of Freiburg
This entry was posted on gennaio 10, 2024 a 6:26 am and is filed under News-research. Tagged: pharmacology, genetics, oncology, urology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.